Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)

China · Delayed Price · Currency is CNY

10.60

0.00 (0.00%)

Apr 30, 2026, 3:00 PM CST

0.76% (1Y)

Market Cap	4.58B
Revenue (ttm)	1.16B
Net Income (ttm)	216.65M
Shares Out	432.33M
EPS (ttm)	0.50
PE Ratio	21.15
Forward PE	n/a
Dividend	0.33 (3.08%)
Ex-Dividend Date	Nov 26, 2025

Volume	1,972,100
Average Volume	2,353,553
Open	10.67
Previous Close	10.60
Day's Range	10.58 - 10.80
52-Week Range	9.62 - 14.94
Beta	0.04
RSI	51.63
Earnings Date	Apr 24, 2026

About Tibet Weixinkang Medicine

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The com... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 689

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603676

Full Company Profile

Financial Performance

In 2025, Tibet Weixinkang Medicine's revenue was 1.14 billion, a decrease of -12.65% compared to the previous year's 1.30 billion. Earnings were 232.85 million, a decrease of -5.41%.

Financial Statements

News

There is no news available yet.